RenovoRx (NASDAQ:RNXT) Issues Earnings Results, Meets Estimates

RenovoRx (NASDAQ:RNXT) announced its earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports. The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.47 million. RenovoRx had a negative return on equity of 148.53% and a negative net margin of 823.98%.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx reported record Q1 2026 revenue of $563,000, up 136% sequentially from Q4 2025 and more than half of full-year 2025 revenue, signaling that its commercial model is starting to scale.
• The company said it now has 16 active commercial cancer centers as of May 2026, up from 8 at year-end 2025, with 32 more centers in the pipeline and a target of 36 centers by year-end.
• Management reiterated full-year 2026 revenue guidance of $3 million to $4 million and said second-quarter revenue is tracking above Q1, which they believe keeps them on plan.
• The TIGeR-PaC Phase III trial is nearing enrollment completion, with 106 of 114 patients randomized and enrollment expected to close in early June, while final data remains expected in mid-to-late 2027.
• RenovoRx completed an oversubscribed $10 million private placement and ended Q1 with $12.4 million in cash, giving it runway into the second half of 2027 as it works toward cash flow breakeven.

RenovoRx Stock Performance

RNXT traded down $0.04 during midday trading on Friday, reaching $0.82. 647,593 shares of the company were exchanged, compared to its average volume of 277,120. The company’s fifty day moving average price is $0.94 and its 200 day moving average price is $0.94. The company has a market cap of $36.94 million, a price-to-earnings ratio of -2.48 and a beta of 1.00. RenovoRx has a one year low of $0.70 and a one year high of $1.45.

Institutional Trading of RenovoRx

Institutional investors have recently made changes to their positions in the company. Wealthspire Advisors LLC bought a new position in shares of RenovoRx in the fourth quarter valued at approximately $212,000. Citadel Advisors LLC bought a new position in shares of RenovoRx in the third quarter valued at approximately $154,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of RenovoRx in the second quarter valued at approximately $98,000. Bleichroeder LP grew its holdings in shares of RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after acquiring an additional 31,730 shares in the last quarter. Institutional investors own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on RNXT shares. JonesTrading raised RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. Ascendiant Capital Markets boosted their price target on shares of RenovoRx from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, April 9th. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of RenovoRx in a research note on Wednesday, April 8th. Finally, Wall Street Zen lowered shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, RenovoRx has a consensus rating of “Moderate Buy” and an average price target of $8.25.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.